Sector Expert: Jason McCarthy

Maxim Group

Image: Jason McCarthy

Jason McCarthy, Ph.D., is an equity research analyst covering the biotechnology industry at Maxim Group. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in biomedical sciences from the Albert Einstein College of Medicine. McCarthy also holds master's degrees in both biomedical research (Albert Einstein College of Medicine) and molecular biology (Adelphi University), as well as a bachelor's degree in biochemistry from Stony Brook University. He closely follows gene therapy, CAR-T and the cancer immunology spaces, as well as many traditional biotechnology companies.



Recent Interviews

Stellar Biotechnologies (SBOT:NASDAQ) Could Rise with KLH Vaccine Trial Success (3/1/17)
Beaker and News Update

Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Maxim currently has a price target of $4 on Stellar and the stock currently trades at around $1.65.

Partnerships Propel Stellar Biotechnologies' Vaccine Technology (6/22/16)
moneyinbeaker63-

Maxim analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc., even though its product originated in the deep blue sea. With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore.

Regenerative Medicine Follows the CAR T-Cell Gravy Train: Maxim Group's Jason Kolbert and Jason McCarthy (12/2/15)
sideways-blue-stemcell580

Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird") in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.

Recent Quotes

"INO's VGX-3100 study should start in 1H17, multiple catalysts ahead in other programs."

— Jason McCarthy, Maxim Group (3/16/17)
more >

"No one else can supply KLH at the quality and the quantity that SBOT can."

The Life Sciences Report Interview with Jason McCarthy (3/1/17)
more >

"End of phase II meetings with both the FDA and EMA have given INO a path forward for a pivotal study of VGX-3100."

— Jason McCarthy, Maxim Group (2/23/17)
more >

— Jason McCarthy, Maxim Group (12/16/16)
more >

— Jason McCarthy, Maxim Group (12/2/16)
more >

"Our focus continues to be on INO's VGX-3100 and the start of the pivotal program as the next major event, now potentially in 2017."

— Jason McCarthy, Maxim Group (10/24/16)
more >

"INO's Zika vaccine candidate generated robust anti-Zika immune responses in non-human primates."

— Jason McCarthy, Maxim Group (5/16/16)
more >

"Data flow from multiple studies in 2016 should continue to provide catalysts for INO's investors."

— Jason McCarthy, Maxim Group (5/9/16)
more >

more comments

"INO completed its acquisition of Needle-Free Technology, which could be a paradigm shifting technology."

— Jason McCarthy, Maxim Group (5/2/16)
more >

"INO's HPV vaccine approach could, beyond initial viral elimination, also induce immune memory, potentially guarding against reinfection."

— Jason McCarthy, Maxim Group (4/27/16)
more >

"In under a year, INO could have the first Zika vaccine in humans."

— Jason McCarthy, Maxim Group (2/12/16)
more >

"INO and GeneOne began patient recruitment in the Phase 1 MERS study."

— Jason McCarthy, Maxim Group (1/28/16)
more >

"Our long-term positive outlook on INO remains unchanged."

— Jason McCarthy, Maxim Group (1/5/16)
more >

"INO is basically dominating the human papillomavirus (HPV)-driven cancer and cervical dysplasia space."

The Life Sciences Report Interview with Jason McCarthy (12/2/15)
more >

"BCLI is ideally positioned to capture interest."

— Jason McCarthy, Maxim Group (11/17/15)
more >

"We believe BCLI's NurOwn is the right approach to ALS."

— Jason McCarthy, Maxim Group (11/16/15)
more >

"Two interim looks are planned for IMUC's ICT-107 Phase 3 trial in GBM."

— Jason McCarthy, Maxim Group (11/16/15)
more >

"Pay attention to what IMUC is doing."

— Jason McCarthy, Maxim Group (11/13/15)
more >

"INO reported Q3/15 with revenues of $24M."

— Jason McCarthy, Maxim Group (11/9/15)
more >

"INO's INO-3112 generated HPV CD8 T-cell responses in 10 patients."

— Jason McCarthy, Maxim Group (11/6/15)
more >

"MSB has shown, so far, that its allogeneic cells are safe."

The Life Sciences Report Interview with Jason McCarthy (9/23/15)
more >

"INO has a very broad pipeline that seems to be moving steadily."

The Life Sciences Report Interview with Jason McCarthy (9/23/15)
more >

"The first subject has been dosed with INO's HIV vaccine, Pennvax-GP."

— Jason McCarthy, Maxim Group (9/9/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.